Nuclera

Nuclera is a biotech company developing desktop protein synthesis technology that enables scientists to produce any protein on demand in a matter of hours, rather than the weeks or months traditionally required. Founded at the University of Cambridge, the company's eProtein Discovery platform democratises access to proteins — the molecules that power all living systems — for researchers across drug discovery, diagnostics and synthetic biology.

The company was co-founded by Jonathan Milner, the serial biotech entrepreneur behind Abcam, alongside Michael Chen, Jiahao Huang and Gordon McInroy. Nuclera's technology uses electrobiological methods to produce proteins at the bench without specialist infrastructure, enabling faster and more flexible research workflows.

In October 2024, Nuclera raised £57 million from a syndicate including British Patient Capital, Cambridge Innovation Capital, E Ink, M&G Catalyst and others, to commercialise its platform globally.